Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients

Folia Histochemica et Cytobiologica

Volumn 50, Issue 2, 2012, Pages 213-219

  Ławicki, Sławomir ^a   Bedkowska, Grazyna E ^a   Gacuta Szumarska, Ewa ^a   Knapp, Paweł ^a   Szmitkowski, Maciej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Cervical cancer; HGFs; SCC Ag; Tumor markers

Indexed keywords

COLONY STIMULATING FACTOR 1; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; STEM CELL FACTOR; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; MICROPARTICLE ENZYME IMMUNOASSAY; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU;

EID: 84863975385     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2012.0030     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global center statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Catellsauge X, Diaz M, de Sajnose S et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006;98:303-315.
3. Averette HE, Janicek MF. Cervical cancer: prevention, diagnosis and therapeutics. CA Cancer J Clin. 2001;51:92-114.
4. De Lande J, Davelaar EM, Mensdorff-Pouilly S et al. SCC-Ag, lymph node metastases and sentinel node procedure in early stage squamous cell cervical cancer. Gynecol Oncol. 2009;112: 119-125.
5. Miyasaka N. Introduction: Cytokine receptors and their classification. Nippon Rinsho. 2005;63:Suppl:S5-9.
6. Chao K, Chang C, Yen M, Wang P, Ng H. Granulocyte colony- stimulating factor on the growth of human ovarian carcinoma cells in vitro. Gynecol Obstet Invest. 1999;48:280-284.
7. Baiocchi G, Kavanagh JJ, Talpaz M, Wharton JT, Gutterman JU, Kurzrock R. Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. Cancer. 1991;67:990-996.
8. Inoue M, Kyo S, Fujita M, Enomoto T, Kondoh G. Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res. 1994;54:3049-3053.
9. Hammes LS, Tekmal RR, Naud P et al. Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Gynecol Oncol. 2008;110:445-451.
10. Kirma N, Hammes LS, Liu YG et al. Elevated expression of the oncogene c-fms and its ligand, the macrophage colony-stimulating factor-1, in cervical cancer and the role of transforming growth factor-beta1 in inducing c-fms expression. Cancer Res. 2007;67:1918-1926.
11. Nasu K, Inoue C, Takai N, Kashima K, Miyakawa I. Squamous cell carcinoma of the cervix producing granulocyte colony- stimulating factor. Obstet Gynecol. 2004;104:1086-1088.
12. Kyo S, Kanaya T, Takakura M, Inoue M. A case of cervical cancer with aggressive tumor growth: possible autocrine growth stimulation by G-CSF and IL-6. Gynecol Oncol. 2000; 78:383-387.
13. Ahn HJ, Park YH, Chang YH et al. A case of uterine cervical cancer presenting with granulocytosis. Korean J Intern Med. 2005;20:247-250.
14. Watanabe A, Wachi T, Omi H et al. Granulocyte colony-stimulating factor-producing small-cell carcinoma of the uterine cervix: report of a case. Diagn Cytopathol. 2000;23:269-274.
15. Ohwada M, Wada T, Saga Y et al. C-kit overexpression in neuroendocrine small cell carcinoma of the uterine cervix. Eur J Gynaecol Oncol. 2006;27:53-55.
16. Haverkos HW. Multifactorial etiology of cervical cancer: a hypothesis. Med Gen Med. 2005;30:57.
17. Bahar B, Cayci B, Coskun U, Buyukberber S, Benekli M, Yildiz R. Granulocyte colony stimulating factor (G-CSF) and macrophage colony stimulating factor (M-CSF) as potential tumor markers in non small cell lung cancer diagnosis. Asian Pacific J Cancer Prev. 2010;11:709-712.
18. Groblewska M, Mroczko B, Wereszczyńska-Siemiatkowska U, Myśliwiec P, Kedra B, Szmitkowski M. Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients. Clin Chem Lab Med. 2007;45:30-34.
19. Yokoama T, Hyodo M, Hosoya Y et al. Aggressive G-CSF-producing gastric cancer complicated by lung and brain abscesses, mimicking metastates. Gastric Cancer. 2005;8: 198-201.
20. Shizmu N, Miyatake R, Esa A. Squamous cell carcinoma of bladder producing granulocyte colony-stimulating factor (G-CSF): a case report. Acta Urol Japonica. 2005;51:121-124.
21. Skates SJ, Horick N, Yu Y et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol. 2004;22:4059-4066.
22. Ławicki S, Bedkowska GE, Gacuta-Szumarska E, Czygier M, Szmitkowski M. The plasma levels and diagnostics utility of stem cell factor and macrophage colony stimulating factor in endometrial cancer patients. Przegl Lek. 2007;64:987-990.
23. Punnonen R, Teisala K, Kuoppala T, Bennett B, Punnonen J. Cytokine production profiles in the peritoneal fluids of patients with malignanat or benign gynecologic tumors. Cancer. 1998;83:788-796.
24. Connor JP. Aggressive carcinosarcoma of the uterine cervix associated with high levels of granulocyte colony stimulating factor: case report and laboratory correlates. Gynecol Oncol. 2006;103:349-353.
25. Ławicki S, Bedkowska GE, Gacuta-Szumarska E, Knapp P, Szmitkowski M. The plasma levels and diagnostics utility of stem cell factor (SCF) and macrophage-colony stimulating factor (M-CSF) in cervical cancer patients. Pol Merkur Lek. 2008;25:38-42.
26. Davelaar EM, Lande J, Mensdorff-Pouilly S, Blankenstein MA, Verheijen RHM, Kenemans P. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer. Tumor Biol. 2008;29:9-17.
27. Kotowicz B, Fuksiewicz M, Kowalska M, Jońska-Gmyrek J, Bidziński M, Kamińska J. The value of tumor marker and cytokine analysis for the assessment of regional lymph node status in cervical cancer patients. Int J Gynecol Cancer. 2008; 18:1279-1284.
28. Pras E, Willemse PH, Canrinus AA et al. Serum squamous cell carcinoma antigen and CYFRA 21-1in cervical cancer treatment. Int J Radiat Oncol Biol Phys. 2002;52:23-32.
29. Strauss HG, Laban C, Lautenschlager C, Buchmann J, Schneider I, Koelbl H. SCC antigen in the serum as an independent prognostic factor in operable squamous cell carcinoma of the cervix. Eur J Cancer. 2002;38:1987-1991.
30. Rocha-Zavaleta L, Huitron C, Caceres-Cortes JR et al. Interleukin-2 (IL-2) receptor-betagamma signaling is activated by c-Kit in the absence of IL-2, or by exogenous IL-2 via JAK3/STAT5 in human papillomavirus-associated cervical cancer. Cell Signal. 2004;16:1239-1247.
31. Wang HL, Lu DW. Overexpression of c-kit protein is an infrequent event in small cell carcinomas of the uterine cervix. Mod Pathol. 2004;17:732-738.
32. Rony AA, Horowitz IR, Tekmal RR. Serum levels of macrophage colony-stimulating factor-1 in cervical human papillomavirus infection and intraepithelial neoplasia. Am J Obstet Gynecol. 1999;180:28-32.
33. Zijlmans HJMA, Fleuren GJ, Baelde HJ, Eilers PHC, Kenter GG, Gorter A. Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-a, and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma. Cancer. 2007;109:556-565.
34. Czygier M, Ławicki S, Szmitkowski M, Mroczko B. Plasma granulocyte-macrophage colony stimulating factor (GM-CSF) and activity of of enzymes in granulocytes of breast cancer patients. Przegl Lek. 2006;63:654-657.
35. Hazelbag S, Fleuren GJ, Baelde JJ, Schuuring E, Kenter GG, Gorter A. Cytokine profile of cervical cancer cells. Gynecol Oncol. 2001;83:235-243.
36. Ławicki S, Czygier M, Gacuta-Szumarska E, Knapp P, Szmitkowski M. The plasma levels and diagnostics utility of granulocyte-colony stimulating factor (G-CSF) and macrophage- colony stimulating factor (M-CSF) in ovarian cancer patients. Pol Merkur Lek. 2006;125:465-468.
37. Ławicki S, Szmitkowski M, Wojtukiewicz M. The pretreatment plasma level and diagnostics utility of M-CSF in benign breast and breast cancer patients. Clin Chim Acta. 2006;371: 112-116.
38. Mroczko B, Szmitkowski M, Okulczyk B. Hematopoietic growth factors in colorectal cancer patients. Clin Chem Lab Med. 2003;41:646-651.
39. Kamińska J, Kowalska M, Kotowicz B et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. Oncology. 2006;70:115-125.
40. Mroczko B, Groblewska M, Wereszczyńska-Siemiatkowska U, Kedra B, Konopko M, Szmitkowski M. The diagnostics value of G-CSF measurement in the sera of colorectal cancer and adenoma patients. Clin Chim Acta. 2006;371:143-147.